Characterization of renal biomarkers for use in clinical trials: Biomarker evaluation in healthy volunteers

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 227-237

  Brott, David A ^a   Adler, Scott H ^a   Arani, Ramin ^a   Lovick, Susan C ^a   Pinches, Mark ^a   Furlong, Stephen T ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Biomarkers; Clinical; Drug development; Healthy volunteers; Kidney; Qualification

Indexed keywords

ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALBINDIN; CLUSTERIN; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; CYSTATIN C; GLUTATHIONE TRANSFERASE ALPHA; KIDNEY INJURY MARKER 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; RENAL BIOMARKER; TAMM HORSFALL GLYCOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TREFOIL PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASSAY; CAUCASIAN; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CORRELATIONAL STUDY; FEMALE; FOOD INTAKE; HUMAN; INTERSUBJECT VARIABILITY; INTRASUBJECT VARIABILITY; MALE; MULTIPLEX VENDOR ASSAY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); SEX; SEX DIFFERENCE; SINGLE ANALYTE ASSAY; STATISTICAL CONCEPTS; URINALYSIS; CLINICAL TRIAL; DRUG EFFECTS; EATING; KIDNEY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; URINE;

ADULT; AGED; BIOLOGICAL MARKERS; EATING; FEMALE; HEALTHY VOLUNTEERS; HUMANS; KIDNEY; MALE; MIDDLE AGED; SEX FACTORS;

EID: 84894800570     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S54956     Document Type: Article

References (50)

1. Star RA. Treatment of acute renal failure. Kidney Int. 1998;54(6): 1817-1831.
2. Uchino S. Creatinine. Curr Opin Crit Care. 2010;16(6):562-567.
3. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol. 2010;28(5):455-462.
4. Harpur E, Ennulat D, Hoffman D, et al. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol Sci. 2011;122(2):235-252.
5. Ozer JS, Dieterle F, Troth S, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010;28(5): 486-496.
6. Guinee DG Jr, van Zee B, Houghton DC. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer. 1993;71(12):4050-4054.
7. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28(5):830-838.
8. Matheis K, Laurie D, Andriamandroso C, et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today. 2011;16(13-14):600-608.
9. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756-766.
10. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med. 2010;38 Suppl 6:S169-S174.
11. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15): 1858-1866.
12. Buelow MW, Dall A, Regner K, et al. Urinary interleukin-18 and urinary neutrophil gelatinase-associated lipocalin predict acute kidney injury following pulmonary valve replacement prior to serum creatinine. Congenit Heart Dis. 2012;7(5):441-447.
13. De Geus HR, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J. 2012;5(2):102-108.
14. Devarajan P, Krawczeski CD, Nguyen MT, Kathman T, Wang Z, Parikh CR. Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am J Kidney Dis. 2010;56(4):632-642.
15. Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant. 2013;28(2): 254-273.
16. Zhang X, Gibson B Jr, Mori R, et al. Analytical and biological validation of a multiplex immunoassay for acute kidney injury biomarkers. Clin Chim Acta. 2013;415:88-93.
17. Huber PJ. Robust Statistics. New York, NY: John Wiley and Sons; 1981.
18. Horn PS, Pesce AJ, Copeland BE. A robust approach to reference interval estimation and evaluation. Clin Chem. 1998;44(3): 622-631.
19. Salimetrics. Interand intraassay coefficients of variability. Available from: http://www.salimetrics.com/documents/spit-tips/publications/Inter%20and%20Intra%20Assay%20Coefficients%20of%20Variability.pdf. Accessed September 1, 2013.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Soc B. 1995;57(1):289-300.
21. Wind RD, Tolboom H, Klare I, Huys G, Knol J. Tolerance and safety of the potentially probiotic strain lactobacillus rhamnosus PRSF-L477: a randomized, double-blind placebo-controlled trial in healthy volunteers. Br J Nutr. 2010;104(12):1806-1816.
22. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med. 2004;351(15): 1548-1563.
23. Delanaye P, Rozet E, Krzesinski JM, Cavalier E. Urinary NGAL measurement: biological variation and ratio to creatinine. Clin Chem Acta. 2011;412(3-4):390.
24. Goldstein SL. Urinary kidney injury biomarkers and urine creatinine normalization: a false premise or not? Kidney Int. 2010;78(5): 433-435.
25. Heavner DL, Morgan WT, Sears SB, Richardson JD, Byrd GD, Ogden MW. Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers' spot and 24-h urines. J Pharm Biomed Anal. 2006;40(4):928-942.
26. Pennemans V, Rigo JM, Faes C, Reynders C, Penders J, Swennen Q. Establishment of reference values for novel urinary biomarkers for renal damage in the healthy population: are age and gender an issue? Clin Chem Lab Med. 2013;51(9):1795-1802.
27. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010;78(5):486-494.
28. Ralib AM, Pickering JW, Shaw GM, et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol. 2012;23(2):322-333.
29. Solberg HE, PetitClerc C. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values. Approved recommendation (1988) on the theory of reference values. Part 3. Preparation of individuals and collection of specimens for the production of reference values. J Clin Chem Clin Biochem. 1988;26(9):593-598.
30. Ichihara K, Boyd JC. An appraisal of statistical procedures used in derivation of reference intervals. Clin Chem Lab Med. 2010;48(11): 1537-1551.
31. Grenier FC, Ali S, Syed H, et al. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin Biochem. 2010;43(6):615-620.
32. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in early diagnosis of acute kidney injury. Kidney Int. 2008;73(7): 863-869.
33. Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200-208.
34. Takashi M, Zhu Y, Miyake K, Kato K. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy. Urol Int. 1996;56(3):174-179.
35. Zheng J, Xiao Y, Yao Y, et al. Comparison of urinary biomarkers for early detection of acute kidney injury after cardiopulmonary bypass surgery in infants and young children. Pediatr Cardiol. 2013;34(4): 880-886.
36. Sasaki D, Yamada A, Umeno H, et al. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers. 2011;16(7):553-566.
37. Häring N, Mähr HS, Mündle M, Strohal R, Lhotta K. Early detection of renal damage caused by fumaric acid ester therapy by determination of urinary β2-microglobulin. Br J Dermatol. 2011;164(3): 648-651.
38. Guha M, Heier A, Price S, et al. Assessment of biomarkers of drug-induced kidney injury in cynomologus monkeys treated with a triple reuptake inhibitor. Toxicol Sci. 2011;120(2):269-283.
39. Betton GR, Ennulat D, Hoffman D, Gautier JC, Harpur E, Pettit S. Biomarkers of collecting duct injury in Han-Wistar and Sprague-Dawley rats treated with N-phenylanthranilic acid. Toxicol Pathol. 2012;40(4):682-694.
40. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol. 2010;28(5):463-469.
41. Riser BL, Cortes P, DeNichilo M, et al. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int. 2003;64(2):451-458.
42. Wunnapuk K, Liu X, Peake P, et al. Renal biomarkers predict nephrotoxicity after paraquat. Toxicol Lett. 2013;222(3):280-288.
43. Aydoǧdu M, Gürsel G, Sancak B, et al. The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers. 2013;34(4):237-246.
44. Pinches M, Betts C, Bickerton S, et al. Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences. Toxicol Pathol. 2012;40(3):522-533.
45. Pai MP, Norenberg JP, Telepak RA, Sidney DS, Yang S. Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate. Antimicrob Agents Chemother. 2005;49(9):3784-3788.
46. Askenazi DJ, Montesanti A, Hunley H, et al. Urine biomarkers predict acute kidney injury and mortality in very low birth weight infants. J Pediatr. 2011;159(6):907-912.
47. Askenazi DJ, Koralkar R, Hundley HE, et al. Urine biomarkers predict acute kidney injury in newborns. J Pediatr. 2012;161(2):270-275.
48. Hörstrup JH, Gehrmann M, Schneider B, et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant. 2002;17(6):1005-1013.
49. Yu Y, Jin H, Holder D, et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol. 2010;38(5):470-477.
50. Astor BC, Köttgen A, Hwang SJ, Bhavsar N, Fox CS, Coresh J. Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the atherosclerosis risk in communities (ARIC) study. Am J Nephrol. 2011;34(4):291-297.